| Objective:To evaluate the efficacy of resveratrol in the treatment of post-stroke depression(PSD),and to explore the correlation between the clinical efficacy of resveratrol in the treatment of PSD and IL-18?TNF-? and hs-CRP.Methods:1.The 65 PSD patients were divided into the resveratrol group(n=22),the sertraline group(n=21),and the control group(n=22).The resveratrol group' patients oral resveratrol capsule(two times a day,300mg/day)and accepted routine treatment.The sertraline group'patients oral sertraline hydrochloride capsules(one time a day,50mg/day,after a week change to 100mg/time)and accepted routine treatment.The control group' patients only accepted routine treatment,Three groups were treated for eight weeks.2.The Hamilton depression scale-24 was used to evaluate the depression of the three groups' patients before treatment,four weeks after treatment and eight weeks after treatment.To analyze the difference of therapeutic effect between resveratrol group,sertraline group and control group.3.Collect the three groups of patients' serum before treatment,after treatment of four weeks and eight weeks.The Enzyme-linked Immunosorbent Assay(ELISA)was used to determine the levels of interleukin-18(IL-18),tumor necrosis factor-?(TNF-?),and hypersensitive C-reactive protein(hs-CRP)in serum samples.The changes of IL-18,TNF-?and hs-CRP in the resveratrol group,sertraline group and control group were analyzed.4.Using the anti-depressant adverse reaction scale(SERS)to record the adverse reactions of drugs in the resveratrol group and the sertraline group during treatment,and the differences of adverse reactions between the two groups were analyzed.Results:1.HAMD-24 score(1)There was no statistically significant difference in HAMD-24 scores between the three groups patients before treatment(P>0.05).(2)The HAMD-24 score of the patients in the resveratrol group and the sertraline group was significantly decreased after treatment of four weeks than that before treatment(P<0.05).The HAMD-24 score of the patients in the control group were not significantly lower than that before treatment(P>0.05).There was no significant difference between the resveratrol group and the control group at after treatment of four weeks(P>0.05).The HAMD-24 scores of patients in the sertraline group were significantly lower than those of the control group at after treatment of four weeks(P<0.05).(3)The HAMD-24 score of the patients in the resveratrol group and the sertraline group have significantly decreased after treatment of eight weeks than that before treatmen and after four weeks of treatment(P<0.05).The HAMD-24 score of the patients in the control group were not significantly lower than that before and after four weeks of treatment(P>0.05).The HAMD-24 scores of patients in the resveratrol group and the sertraline group were significantly lower than those of the control group at after treatment of eight weeks(P<0.05).The HAMD-24 scores of patients in the sertraline group were significantly lower than those of the resveratrol group at after treatment of eight weeks(P<0.05).2.Detection results of inflammatory factor(1)There was no statistically significant difference in the levels of IL-18?TNF-?and hs-CRP between the three groups patients before treatment(P>0.05).(2)The levels of IL-18 ? TNF-? and hs-CRP of the three groups' patients were significantly decreased after treatment of four weeks than that before treatment(P<0.05).There was no significant difference between the resveratrol group and the control group at after treatment of four weeks(P>0.05).The levels of IL-18 ? TNF-? and hs-CRP of the sertraline group' patients were significantly lower than those of the control group(P<0.05).(3)The levels of IL-18 ? TNF-? and hs-CRP of the three groups' patients haven significantly decreased after treatment of eight weeks than those of before and after four weeks of treatment(P<0.05).The levels of IL-18 ?TNF-?and hs-CRP of patients in the resveratrol group and the sertraline group were significantly lower than those of the control group at after treatment of eight weeks(P<0.05).The levels of IL-18?TNF-?and hs-CRP of patients in the resveratrol group were lower than those of the sertraline group(P<0.05).3.Clinical observationIn the resveratrol group,three cases were cured,five cases were significantly effective,four cases were effective,and ten cases were ineffective,and the total effective rate of 54.54%.In the sertraline group,six cases were cured,eight cases were significantly effective,two cases were effective,five cases were ineffective,and the total effective rate was 76.19%.In the control group,zero cases were cured,one cases was obviously effective,two cases were effective,nineteen cases were ineffective,and the total effective rate was 13.64%.The total effective rate of resveratrol group and sertraline group was significantly higher than those of the control group(P<0.0125).The total effective rate of resveratrol group were not significantly lower than sertraline group(P>0.0125).4.Adverse reactions of resveratrol or sertraline:The incidence rate of adverse reactions in the resveratrol group was only 4.55%,and in the sertraline group was 19.05%,The incidence of adverse reactions between the two groups was compared(P>0.05),and the difference was not statistically significant.Conclusion:Resveratrol is effective in the treatment of post-stroke depression,and it is anti-depressant effect may be to inhibit the inflammatory response of post-stroke depression by reducing the levels of IL-18?TNF-??hs-CRP and other inflammatory cytokines. |
PDF Full Text Request